Literature DB >> 7903454

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

I Johansson1, E Lundqvist, L Bertilsson, M L Dahl, F Sjöqvist, M Ingelman-Sundberg.   

Abstract

Deficient hydroxylation of debrisoquine is an autosomal recessive trait that affects approximately 7% of the Caucasian population. These individuals (poor metabolizers) carry deficient CYP2D6 gene variants and have an impaired metabolism of severely commonly used drugs. The opposite phenomenon also exists, and certain individuals metabolize the drugs very rapidly, resulting in subtherapeutic plasma concentrations at normal doses. In the present study, we have investigated the molecular genetic basis for ultrarapid metabolism of debrisoquine. Restriction fragment length polymorphism analysis of the CYP2D locus in two families with very rapid metabolism of debrisoquine [metabolic ratio (MR) for debrisoquine = 0.01-0.1] revealed the variant CYP2D6 gene CYP2D6L. Eco RI RFLP and Xba I pulsed-field gel electrophoresis analyses showed that this gene had been amplified 12-fold in three members (father and his two children) of one of the families, and two copies were present among members of the other family. The CYP2D6L gene had an open reading frame and carried two mutations causing amino acid substitutions: one in exon 6, yielding an Arg-296-->Cys exchange and one in exon 9 causing Ser-486-->Thr. The MR of subjects carrying one copy of the CYP2D6L gene did not significantly differ from that of those with the wild-type gene, indicating that the structural alterations were not of importance of the catalytic properties of the gene product. Examination of the MR among subjects carrying wild-type CYP2D6, CYP2D6L, or deficient alleles revealed a relationship between the number of active genes and MR. The data show the principle of inherited amplification of an active gene. Furthermore, the finding of a specific haplotype with two or more active CYP2D6 genes allows genotyping for ultrarapid drug metabolizers. This genotyping could be of predictive value for individualized and more efficient drug therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903454      PMCID: PMC48077          DOI: 10.1073/pnas.90.24.11825

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells.

Authors:  G M Wahl; R A Padgett; G R Stark
Journal:  J Biol Chem       Date:  1979-09-10       Impact factor: 5.157

Review 2.  Human cancer and cellular oncogenes.

Authors:  S Nishimura; T Sekiya
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

3.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

Authors:  L Bertilsson; M L Dahl; F Sjöqvist; A Aberg-Wistedt; M Humble; I Johansson; E Lundqvist; M Ingelman-Sundberg
Journal:  Lancet       Date:  1993-01-02       Impact factor: 79.321

Review 4.  Gene amplification in cultured animal cells.

Authors:  R T Schimke
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

Review 5.  Gene amplification.

Authors:  G R Stark; G M Wahl
Journal:  Annu Rev Biochem       Date:  1984       Impact factor: 23.643

6.  c-Ha-ras-1 proto-oncogene amplification and overexpression during the limited replicative life span of normal human fibroblasts.

Authors:  A Srivastava; J S Norris; R J Shmookler Reis; S Goldstein
Journal:  J Biol Chem       Date:  1985-05-25       Impact factor: 5.157

7.  Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells.

Authors:  F W Alt; R E Kellems; J R Bertino; R T Schimke
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

8.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

Authors:  L Bertilsson; A Aberg-Wistedt; L L Gustafsson; C Nordin
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

9.  In vivo somatic mutations in human lymphocytes frequently result from major gene alterations.

Authors:  D R Turner; A A Morley; M Haliandros; R Kutlaca; B J Sanderson
Journal:  Nature       Date:  1985 May 23-29       Impact factor: 49.962

Review 10.  DNA amplification in drug resistant cells and in tumours.

Authors:  G R Stark
Journal:  Cancer Surv       Date:  1986
View more
  123 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 3.  Science, medicine, and the future: Pharmacogenetics.

Authors:  C R Wolf; G Smith; R L Smith
Journal:  BMJ       Date:  2000-04-08

4.  CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.

Authors:  S Panserat; L Sica; N Gérard; H Mathieu; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 5.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 6.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 7.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

8.  Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors:  Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

9.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

10.  Objective assessment of nonadherence and unknown co-medication in hospitalized patients.

Authors:  Florentine Carow; Karin Rieger; Ingeborg Walter-Sack; Markus R Meyer; Frank T Peters; Hans H Maurer; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2012-02-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.